MARKET

LGND

LGND

Ligand Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

93.18
+3.62
+4.04%
After Hours: 90.90 -2.28 -2.45% 17:35 09/23 EDT
OPEN
99.60
PREV CLOSE
89.56
HIGH
99.60
LOW
92.64
VOLUME
780.03K
TURNOVER
--
52 WEEK HIGH
127.80
52 WEEK LOW
57.24
MARKET CAP
1.50B
P/E (TTM)
-67.6639
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ligand forecasts big jump in Captisol material sales in 2021
Ligand Pharmaceuticals ([[LGND]] +5.0%) expects Captisol material sales of ~$200M in 2021 compared to its 2020 full-year expectation of $90M.The company said “recent new contracting with partners and investments in
Seekingalpha · 13h ago
Ligand forecasts Captisol material sales more than double in 2021
Ligand Pharmaceuticals ([[LGND]] +5.0%) expects Captisol material sales of ~$200M in 2021 compared to its 2020 full-year expectation of $90M.The company said “recent new contracting with partners and investments in
Seekingalpha · 13h ago
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and position Captisol for major growth. Significant
Business Wire · 16h ago
Ligand Pharmaceuticals Enters Oversold Territory
Ligand Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks · 5d ago
Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for
Business Wire · 09/10 13:00
LGND or ALKS: Which Is the Better Value Stock Right Now?
LGND vs. ALKS: Which Stock Is the Better Value Option?
Zacks · 09/09 15:40
Merger Arbitrage Mondays - Rosetta Stone Acquired At A Huge Premium
Merger activity increased last week with four new deals announced.The acquisition of Rosetta Stone by Cambium Learning Group.The acquisition of Aimmune Therapeutics by Sociétés des Produits Nestlé.
Seekingalpha · 09/07 18:24
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off.
Benzinga · 09/06 17:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LGND. Analyze the recent business situations of Ligand Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LGND stock price target is 191.80 with a high estimate of 229.00 and a low estimate of 155.00.
EPS
Institutional Holdings
Institutions: 430
Institutional Holdings: 26.18M
% Owned: 162.83%
Shares Outstanding: 16.08M
TypeInstitutionsShares
Increased
81
1.48M
New
72
126.24K
Decreased
113
2.20M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Non-Executive Chairman/Independent Director
John Kozarich
President/Chief Operating Officer
Matthew Foehr
Chief Executive Officer/Director
John Higgins
Chief Financial Officer/Executive Vice President - Finance
Matthew Korenberg
Senior Vice President/General Counsel/Secretary
Charles Berkman
Independent Director
Jason Aryeh
Independent Director
Sarah Boyce
Independent Director
Todd Davis
Independent Director
Nancy Gray
Independent Director
John LaMattina
Independent Director
John Lamattina
Independent Director
Sunil Patel
Independent Director
Stephen Sabba
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
03/20/2007
Dividend USD 2.5
04/03/2007
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LGND
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.